These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11231613)

  • 1. Immune privilege or inflammation? Insights into the Fas ligand enigma.
    O'Connell J; Houston A; Bennett MW; O'Sullivan GC; Shanahan F
    Nat Med; 2001 Mar; 7(3):271-4. PubMed ID: 11231613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R; Emi M; Tanabe K; Uchida Y; Toge T
    Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
    Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
    Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fas signalling pathway and its role in the pathogenesis of cancer.
    Houston A; O'Connell J
    Curr Opin Pharmacol; 2004 Aug; 4(4):321-6. PubMed ID: 15251123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial ovarian cancer cells secrete functional Fas ligand.
    Abrahams VM; Straszewski SL; Kamsteeg M; Hanczaruk B; Schwartz PE; Rutherford TJ; Mor G
    Cancer Res; 2003 Sep; 63(17):5573-81. PubMed ID: 14500397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. See no evil, hear no evil, do no evil: the lessons of immune privilege.
    Niederkorn JY
    Nat Immunol; 2006 Apr; 7(4):354-9. PubMed ID: 16550198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level.
    Frängsmyr L; Baranov V; Nagaeva O; Stendahl U; Kjellberg L; Mincheva-Nilsson L
    Mol Hum Reprod; 2005 Jan; 11(1):35-41. PubMed ID: 15579659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Fas ligand in the bovine oviduct.
    Bergqvist AS; Killian G; Erikson D; Hoshino Y; Båge R; Sato E; Rodríguez-Martínez H
    Anim Reprod Sci; 2005 Mar; 86(1-2):71-88. PubMed ID: 15721660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local adenoviral expression of Fas ligand upregulates pro-inflammatory immune responses in the CNS.
    Regardsoe EL; McMenamin MM; Charlton HM; Wood MJ
    Gene Ther; 2004 Oct; 11(19):1462-74. PubMed ID: 15306838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balanced regulation of mRNA production for Fas and Fas ligand in lymphocytes from centenarians: how the immune system starts its second century.
    Pinti M; Troiano L; Nasi M; Bellodi C; Ferraresi R; Mussi C; Salvioli G; Cossarizza A
    Circulation; 2004 Nov; 110(19):3108-14. PubMed ID: 15505087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of IL-17 in Fas ligand-induced inflammation.
    Umemura M; Kawabe T; Shudo K; Kidoya H; Fukui M; Asano M; Iwakura Y; Matsuzaki G; Imamura R; Suda T
    Int Immunol; 2004 Aug; 16(8):1099-108. PubMed ID: 15237105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-cleavable mutant Fas ligand transfection of donor cornea abrogates ocular immune privilege.
    Sano Y; Yamada J; Ishino Y; Adachi W; Kawasaki S; Suzuki T; Kinoshita S; Okuyama T; Azuma N
    Exp Eye Res; 2002 Oct; 75(4):475-83. PubMed ID: 12387794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
    Lee SH; Bar-Haim E; Goldberger O; Reich-Zeliger S; Vadai E; Tzehoval E; Eisenbach L
    Immunol Lett; 2004 Feb; 91(2-3):119-26. PubMed ID: 15019279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.